Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Drop in Short Interest

by · The Markets Daily

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,452,613 shares, a decline of 51.0% from the June 15th total of 2,962,839 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily volume of 1,062,756 shares, the short-interest ratio is presently 1.4 days.

Theriva Biologics Trading Up 1.2%

Shares of TOVX stock traded up $0.00 during mid-day trading on Wednesday, reaching $0.24. The stock had a trading volume of 560,830 shares, compared to its average volume of 2,665,299. Theriva Biologics has a 1-year low of $0.16 and a 1-year high of $0.86. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11. The business’s fifty day moving average is $0.28 and its 200-day moving average is $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.30 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $1.00.

Get Our Latest Stock Analysis on TOVX

Institutional Trading of Theriva Biologics

An institutional investor recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC increased its holdings in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) by 651.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 212,087 shares of the company’s stock after purchasing an additional 183,878 shares during the period. Geode Capital Management LLC owned approximately 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.17% of the stock is currently owned by institutional investors.

Theriva Biologics Company Profile

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.

Further Reading